{"entity":{"id":"omicxhealth","kind":"company","name":"OmicXHealth","aka":["OMICXHEALTH, INC.","OmicXHealth Inc"],"tldr":"OmicXHealth is a California company developing OmicXScreen, a blood test that uses whole-genome sequencing and machine learning to look for early liver cancer and, later, other cancers.","summary":"OmicXHealth Inc., of San Ramon, California, develops OmicXScreen, an AI and genomics platform for a blood test for early cancer detection that sequences the whole genome once and performs the analysis in software. The company reports preclinical validation in liver cancer (hepatocellular carcinoma), a completed lung cancer classifier and a proof of concept across six cancer types as part of a multi-cancer early detection roadmap. In fiscal year 2026 the National Cancer Institute funded its SBIR project on OmicXScreen, a DNA methylation profiling test for early hepatocellular carcinoma and oesophageal cancer detection (1R43CA310377-01A1, USD 405,305); the company says the grant funds a blinded validation study for early liver cancer detection at UT Southwestern.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.omicxhealth.com/"},{"label":"NIH RePORTER: 1R43CA310377-01A1","url":"https://reporter.nih.gov/project-details/11404601"}],"tags":[],"related":[],"cancers":["hcc","esophageal"],"sections":["early-detection","diagnostics"],"technologies":["cfdna-methylation-testing","mced"],"targets":[],"drugs":["omicxscreen"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on omicxhealth.com and the NIH RePORTER record on 4 November 2026. Validation statements are the company's own."],"hq":"San Ramon, CA","country":"US","companyType":"diagnostics","website":"https://www.omicxhealth.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":405305,"source":"https://reporter.nih.gov/project-details/11404601","note":"NCI SBIR Phase I (R43) award 1R43CA310377-01A1: OmicXScreen: AI/ML-Powered, DNA Methylation Profiling Test for Early HCC and Esophageal Cancer Detection"}]},"route":"/companies/omicxhealth/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"cfdna-methylation-testing","kind":"technology","name":"Cell-free DNA methylation tests","route":"/technologies/cfdna-methylation-testing/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"omicxscreen","kind":"drug","name":"OmicXScreen","route":"/drugs/omicxscreen/"}]}}